WASHINGTON, March 1 (Reuters) - Promotional material for Cephalon Inc.'s sleep drug Provigil circulated at a public meeting made misleading claims that the prescription medicine could treat fatigue, U.S. regulators said in a warning letter to the company released on Thursday.
